NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

ABBOTT’S AMPLATZER™ AMULET™ DEVICE APPROVED BY FDA TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE

by Ed Johnson
August 17, 2021
A A

– Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn’t needed following implantation

– The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common sustained cardiac arrhythmia

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage (LAA) – an area where blood clots can form in people suffering from AFib – reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.

The LAA is a small pouch connected to the upper left chamber of the heart. For people with AFib – the most common of the persistent arrhythmias, or irregular heartbeats – the heart’s ability to effectively pump blood can be disrupted, allowing blood to pool and collect in the LAA causing an increased risk for clotting. If clots reach the blood stream, they can travel to the brain and cause a stroke. For patients with AFib who are unable to take blood-thinning medication long term, physicians may opt for occlusion (or closure) of the LAA through a minimally invasive procedure using devices like Abbott’s Amulet to seal off the LAA entirely and reduce the risk of stroke.

“As the world’s population continues to age, we’re seeing a surge in atrial fibrillation cases, and with that comes increased risk of stroke,” said Dhanunjaya Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health, who served as principal investigator for the study that led to FDA approval. “The approval of Abbott’s Amulet device provides physicians with a treatment option that reduces the risk of stroke and eliminates the need for blood-thinning medication immediately after the procedure, which is incredibly valuable given the bleeding risks associated with these medicines.”

Before this approval, the only minimally invasive option for LAA occlusion for U.S. physicians and their patients was a solution with a single component to seal the LAA that requires blood-thinning drugs to heal and additional patient monitoring to ensure closure. In contrast, Abbott’s Amulet uses dual-seal technology to completely and immediately seal the LAA. Amulet recipients do not need to use blood-thinning medication following the procedure. Additionally, the device can treat a broad range of anatomies and has the widest range of occluder sizes on the market; it is also recapturable and repositionable to ensure optimal placement.

“Amulet’s unique dual-seal approach has made it the number one LAA closure product in Europe, so today’s device approval by the FDA is an important milestone in allowing us to bring this treatment option to American physicians and patients,” said Michael Dale, senior vice president of Abbott’s structural heart business. “Consistent with our mission purpose, our minimally invasive Amulet procedure for reducing stroke risk in patients with atrial fibrillation will help people live better lives through better health.”

Tags: < Innovation
ShareTweetShareSend

Related Industries

Healthcare

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

September 20, 2023
Healthcare

BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards

September 20, 2023
Healthcare

Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes

September 6, 2023
Healthcare

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

September 2, 2023
Healthcare

Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.

August 24, 2023
Healthcare

Microsoft and Epic expand AI collaboration to accelerate generative AI’s impact in healthcare, addressing the industry’s most pressing needs

August 23, 2023

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

September 2, 2023

...

KKR Increases Investment in USI Insurance Services

September 12, 2023

...

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

September 20, 2023

...

Bryan Hanson Named CEO of 3M’s Health Care Business Group

August 23, 2023

...

Vale and H2 Green Steel sign agreement to study the development of green industrial hubs in Brazil and North America

September 7, 2023

...

A.P. Moller – Maersk teams with Fabric to implement AI-driven automated fulfillment center for E-commerce

September 13, 2023

...

Dow innovations recognized with Sustainability Product of the Year awards from the Business Intelligence Group

September 15, 2023

...

Kohler Co. Named in Fast Company’s ‘Best Workplaces for Innovators 2023: Sustained Excellence’ List

August 29, 2023

...

Lenovo and VMware Expand Partnership to Bring New NVIDIA-Powered Turnkey Generative AI and Multi-Cloud Solutions to Every Business

August 23, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NORTH AMERICAN BUSINESS All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NORTH AMERICAN BUSINESS All rights reserved.